Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | HPGD | P15428 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | CDH1 | P12830 | 1/20 | 0.73 |
| ▸ | APC | P25054 | 1/20 | 0.73 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.73 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555665 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15666427 | 0.97 | HPGD (0.93) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665863 | 0.97 | HPGD (0.93) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665725 | 0.94 | HPGD (0.88) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665929 | 0.92 | ALDH1A1 (0.85) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665854 | 0.92 | HPGD (0.85) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL11623030 | 0.91 | ALDH1A1 (0.82) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665468 | 0.91 | CDH1 (0.91) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL11621542 | 0.91 | ALDH1A1 (0.82) | ALDH1A1HPGDKDM4EGAARAB9A | |
| SCHEMBL15665960 | 0.91 | ALDH1A1 (0.91) | ALDH1A1HPGDKDM4EGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230052363-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-16 | — | — | US | disclosed |
| US-9370522-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-6974857-B1 | End-capped quinoxaline-containing hyperbranched aromatic poly(ether-ketones) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2005-12-13 | — | — | US | disclosed |
| US-6608171-B1 | Containing solubilizing pendant groups or flexible units; processability | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE | 2003-08-19 | — | — | US | disclosed |
| US-6541633-B1 | 2,3-bis(3-amino-4-hydroxy or 4-mercapto or 4-NH2.HCLphenyl)quinoxaline-6- carboxylic acid dihydrochloride monomer, which self-polymerizes to form hyperbranched polybenzoxazoles, polybenzothizoles etc. | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | GCDH, HPGD, HAGH | ALDH1A1 86/4885HPGD 2/4885KDM4E 3208/4885 |
| US-20230052363-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | GLS, REN, PTGS1 | ALDH1A1 385/4885HPGD 4/4885KDM4E 4152/4885 |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885HPGD 824/4885KDM4E 3115/4885 |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | HPGD, GCDH, HPGDS | ALDH1A1 136/4885HPGD 1/4885KDM4E 3261/4885 |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | ALDH1A1 136/4885HPGD 1/4885KDM4E 3261/4885 |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3255/4885HPGD 597/4885KDM4E 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.